Mylan’s Generic Copaxone Launch Should Keep Year-End Performance on Track
Although Mylan’s third-quarter results continue to reflect pressure on EpiPen and the U.S. generics business with a 2% decline in revenue and a 20% decline in adjusted EPS, the launch of generic Copaxone should dramatically improve year-end results. Mylan's generic version had about 16% market share in new Copaxone prescriptions as of late October. As a result, the company’s performance remains in line with our expectations, and our year-end adjusted EPS estimate of $4.58 is at the midpoint of m...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.